pharmanewsdaily

US biotech company CinDome Pharma has enrolled the first patient in a phase 2 clinical trial which will evaluate its investigational gastroparesis drug deuterated domperidone (CIN-102). Considered to be a debilitating, chronic condition, gastroparesis impacts the stomach muscles and leads to improper emptying of the stomach. Deuterated domperidone (CIN-102), which has been developed through deuteration […]

The post CinDome Pharma begins phase 2 trial of gastroparesis drug CIN-102 appeared first on PharmaNewsDaily.com.

Themis Bioscience, an Austrian biopharma company, has raised €40 million in a Series D financing round backed by a US/EU Consortium to advance its MV-CHIK Chikungunya vaccine into a phase 3 clinical trial program. The funding round of the Austrian pharma company was co-led by new investors – Farallon Capital and Hadean Ventures. Pharma giant MSD […]

The post Themis Bioscience rakes in €40m to advance MV-CHIK Chikungunya vaccine appeared first on PharmaNewsDaily.com.

US biopharma company Sound Pharmaceuticals said that its investigational drug SPI-1005 has secured the fast track designation (FTD) from the US Food and Drug Administration (FDA) for the treatment of Meniere’s Disease (MD), a disorder of the inner ear. The FTD was granted by the FTD’s Division of Neurology Products, which is for drugs that can […]

The post Sound Pharmaceuticals bags FDA fast track status for SPI-1005 in Meniere’s Disease appeared first on PharmaNewsDaily.com.

Mindmed acquisition of 18-MC : Canada-based Mind Medicine (Mindmed) has acquired opioid addiction drug candidate 18-MC from Savant HWP for an undisclosed price, as per the latest pharma acquisition news. 18-MC, which is derived from ibogaine – a natural psychedelic substance, is being developed for addressing the opioid crisis and other types of addiction. The […]

The post Mindmed acquires 18-MC opioid addiction drug candidate from Savant HWP appeared first on PharmaNewsDaily.com.

Cutera said that Health Canada has expanded approval for its truSculpt iD body sculpting treatment to cover its use for the reduction of circumference of the abdomen and non-invasive lipolysis, which is the permanent removal of fat cells from the body. According to American Society for Aesthetic Plastic Surgery and Medical Insight (MII), noninvasive body sculpting […]

The post Cutera truSculpt iD body sculpting treatment gets expanded approval in Canada appeared first on PharmaNewsDaily.com.

Rozlytrek FDA approval : Roche’s subsidiary Genentech has bagged approvals for Rozlytrek (entrectinib) from the US Food and Drug Administration (FDA) for a type of non-small cell lung cancer (NSCLC) and for certain forms of solid tumors. The first Rozlytrek FDA approval is for the treatment of ROS1-positive, metastatic NSCLC in adult patients. Additionally, Rozlytrek […]

The post Genentech bags Rozlytrek FDA approval for two rare types of cancer appeared first on PharmaNewsDaily.com.

Nucala FDA approval : GlaxoSmithKline (GSK) has secured approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) for the treatment of severe eosinophilic asthma in children, aged six years and older. Nucala, which is a monoclonal antibody that targets IL-5, is now the only targeted biologic to be approved by the FDA […]

The post GSK bags Nucala FDA approval for severe eosinophilic asthma in 6-11 years age group appeared first on PharmaNewsDaily.com.

US precision medicine company Gemini Therapeutics, which is focused on developing treatments for age-related macular degeneration (AMD) and linked ocular disorders, has appointed Jason Meyenburg as its Chief Executive Officer (CEO). Jason Meyenburg will also join the Board of Directors of Gemini Therapeutics. Stephen Squinto – Gemini Therapeutics Board Director said: “We are thrilled to have […]

The post Gemini Therapeutics appoints Jason Meyenburg as CEO appeared first on PharmaNewsDaily.com.